EPO and bronchopulmonary dysplasia: Collectively, we report the proof of principle demonstration that EPO‐MSCs administration can significantly attenuate BPD neonatal mice lung injury in early than in late transplantation, the underlying mechanism maybe through inhibition of inflammation by down‐regulation of the p38MAPK signalling pathway, and further studies would be useful.